Saturday, April 27, 2024

Saturday, April 27, 2024

Latest News

VIZIENT, INC.: Expresses Concern with FDA Policy on Naming of Biologic Medications

Vizient, Inc. today submitted comments to the Food and Drug Administration (FDA) in response to its published draft guidance on the nonproprietary naming of biological products.

HI-TECH PHARMACEUTICALS, INC.: Sues The FDA For "Its Campaign of Intimidation"

Hi-Tech Pharmaceuticals sued the FDA May 2nd, 2019 in Federal Court- Case 1:19-cv-01268, claiming the agency bypassed standard rule-making procedures in favor of a campaign of intimidation to try to force companies to destroy their products containing 2-Aminoisopheptane, or DMHA.

FDA to host hearing on cannabis products

The FDA will have a hearing on scientific data and information about products containing cannabis or cannabis-derived compounds on May 31 from 8 a.m. to 6 p.m.

SYSTECH INTERNATIONAL: Optimal Solution team selected for FDA DSCSA Pilot Program

"The Optimal Solution" is a team of seasoned industry innovators cooperatively leveraging their expertise to demonstrate interoperability at scale in the pharma supply chain ecosystem. Team members include: RXTransparent, Systech, T-Systems, FarmaTrust, Cryptowerk and CalQLogic.

Revamped FDA website to launch this week

Food and Drug Administration Acting Commissioner Ned Sharpless announced a new FDA.org website to launch this week.

Responsible innovation in dietary supplements to be discussed at FDA public meeting

As part of a continuing effort to modernize and reform the oversight of dietary supplements, the Food and Drug Administration announced a public meeting on May 16 from 8:30 a.m. to 4 p.m. to canvass ideas on facilitating responsible innovation.

Corey Polen battles for right to receive ALS medication

Corey Polen was a healthy 40-year-old man enjoying his life with his wife and three children. In October of 2015 that all changed when he started feeling spurts of weakness, not thinking too much about it until it began to progress rapidly with no answers.

FDA could be prohibiting terminal patients from life-saving treatments and medication

The world of pharmaceuticals and biotechnology is ever-growing and changing, but seemingly only behind closed doors.

FDA assesses duoenoscope contamination risk

The Food and Drug Administration oversees manufacturers’ postmark surveillance studies on new and significant health concerns in order to understand a device’s risks and to update policies on such risks.

Medical device makers likely to benefit from ‘similar product’ expedited approval process in 2019

Keeping pace with technology that seems to develop at the speed of light and getting medical treatments to the people who most need them as quickly as possible while still maintaining top standards and keeping patients safe is tricky for the U.S. Food and Drug Administration, but that is its job.

FDA Reporter